Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRX NASDAQ:PCSA NASDAQ:SCNI NASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$3.36-2.0%$3.52$2.86▼$66.50$6.85M1.2327,233 shs28,844 shsPCSAHeatwurx$2.52-8.4%$2.74$1.76▼$19.64$7.56M167,795 shs32,059 shsSCNIScinai Immunotherapeutics$0.41-6.1%$0.56$0.37▼$3.48$1.74M2.05215,653 shs1.26 million shsXBIOXenetic Biosciences$3.09-9.9%$3.10$1.90▼$13.93$7.86M2.1913,774 shs11,792 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals-4.46%+2.08%-23.44%-24.28%-94.09%PCSAHeatwurx-1.79%+4.17%+3.38%-2.83%-64.24%SCNIScinai Immunotherapeutics-3.09%-2.31%-29.79%-43.72%-82.58%XBIOXenetic Biosciences+2.69%+11.36%+11.00%+49.78%+8.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$3.36-2.0%$3.52$2.86▼$66.50$6.85M1.2327,233 shs28,844 shsPCSAHeatwurx$2.52-8.4%$2.74$1.76▼$19.64$7.56M167,795 shs32,059 shsSCNIScinai Immunotherapeutics$0.41-6.1%$0.56$0.37▼$3.48$1.74M2.05215,653 shs1.26 million shsXBIOXenetic Biosciences$3.09-9.9%$3.10$1.90▼$13.93$7.86M2.1913,774 shs11,792 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals-4.46%+2.08%-23.44%-24.28%-94.09%PCSAHeatwurx-1.79%+4.17%+3.38%-2.83%-64.24%SCNIScinai Immunotherapeutics-3.09%-2.31%-29.79%-43.72%-82.58%XBIOXenetic Biosciences+2.69%+11.36%+11.00%+49.78%+8.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 1.00SellN/AN/APCSAHeatwurx 2.00Hold$25.00892.06% UpsideSCNIScinai Immunotherapeutics 1.00SellN/AN/AXBIOXenetic Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCNI, XBIO, PCSA, and BDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/13/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/29/2026BDRXBiodexa Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026PCSAHeatwurx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SCNIScinai Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026XBIOXenetic Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K14.30N/AN/A$110.30 per share0.03PCSAHeatwurxN/AN/AN/AN/A$2.46 per shareN/ASCNIScinai Immunotherapeutics$1.31M1.25N/AN/A$0.78 per share0.53XBIOXenetic Biosciences$2.98M2.37N/AN/A$3.23 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$8.42MN/AN/AN/AN/AN/AN/AN/AN/APCSAHeatwurx-$13.56M-$9.29N/AN/AN/AN/A-281.31%-200.80%8/6/2026 (Estimated)SCNIScinai Immunotherapeutics-$8.31M-$9.57N/AN/AN/AN/AN/AN/A7/7/2026 (Estimated)XBIOXenetic Biosciences-$2.68M-$1.20N/AN/AN/A-70.03%-39.28%-33.47%8/7/2026 (Estimated)Latest SCNI, XBIO, PCSA, and BDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026XBIOXenetic BiosciencesN/A-$0.20N/A-$0.20N/A$0.81 million4/1/2026Q4 2025SCNIScinai ImmunotherapeuticsN/A$3.80N/A$3.80N/A$0.27 million3/27/2026Q4 2025BDRXBiodexa Pharmaceuticals-$0.0066$3.5250+$3.5316-$5.35N/AN/A3/12/2026Q4 2025XBIOXenetic Biosciences-$0.52-$0.22+$0.30-$0.22$0.69 million$0.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/APCSAHeatwurxN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa PharmaceuticalsN/A2.032.03PCSAHeatwurxN/A0.980.98SCNIScinai Immunotherapeutics0.121.301.30XBIOXenetic BiosciencesN/A7.937.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%PCSAHeatwurx91.93%SCNIScinai Immunotherapeutics58.41%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%PCSAHeatwurx2.40%SCNIScinai Immunotherapeutics60.90%XBIOXenetic Biosciences7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals202.00 million1.99 millionNot OptionablePCSAHeatwurx202.75 million2.68 millionNot OptionableSCNIScinai Immunotherapeutics203.96 million1.55 millionNot OptionableXBIOXenetic Biosciences42.29 million2.12 millionNot OptionableSCNI, XBIO, PCSA, and BDRX HeadlinesRecent News About These CompaniesXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...June 4 at 10:58 PM | finance.yahoo.comXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell LymphomaJune 4 at 8:40 AM | accessnewswire.comAXenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and SurvivalJune 1, 2026 | accessnewswire.comAXenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology PlatformMay 13, 2026 | accessnewswire.comAXenetic Biosciences: Q1 Earnings SnapshotMay 12, 2026 | wtop.comWXenetic Biosciences Grants Equity Award to Interim CEOApril 27, 2026 | theglobeandmail.comXenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual MeetingApril 22, 2026 | accessnewswire.comAXenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsMarch 13, 2026 | accessnewswire.comAXenetic Biosciences, Inc. Announces Adjournment of 2025 Annual MeetingDecember 11, 2025 | accessnewswire.comAXenetic extends R&D collaboration with The Scripps Research InstituteNovember 19, 2025 | msn.comXenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase PlatformNovember 19, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Third Quarter 2025 Financial ResultsNovember 13, 2025 | accessnewswire.comAXenetic Biosciences Announces Public Offering PricingOctober 14, 2025 | msn.comXenetic 735,000 share Spot Secondary priced at $6.12October 10, 2025 | msn.comMicron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking SurgesOctober 10, 2025 | benzinga.comXenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common StockOctober 10, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | accessnewswire.comAXenetic Biosciences Reports Improved Financial PerformanceAugust 13, 2025 | msn.comXenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue EstimatesAugust 12, 2025 | zacks.comXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaJuly 30, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCNI, XBIO, PCSA, and BDRX Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$3.36 -0.07 (-2.04%) Closing price 04:00 PM EasternExtended Trading$3.32 -0.03 (-1.04%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Heatwurx NASDAQ:PCSA$2.52 -0.23 (-8.36%) Closing price 04:00 PM EasternExtended Trading$2.50 -0.02 (-0.99%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.Scinai Immunotherapeutics NASDAQ:SCNI$0.41 -0.03 (-6.08%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.03 (+6.23%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Xenetic Biosciences NASDAQ:XBIO$3.09 -0.34 (-9.91%) Closing price 03:59 PM EasternExtended Trading$3.22 +0.13 (+4.05%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
